Literature DB >> 11091200

FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.

F M Abu-Duhier1, A C Goodeve, G A Wilson, M A Gari, I R Peake, D C Rees, E A Vandenberghe, P R Winship, J T Reilly.   

Abstract

Genomic DNA from 106 cases of adult de novo acute myeloid leukaemia (AML) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3 internal tandem duplication (ITD) mutations within the juxtamembrane (JM) domain. FLT3 mutations were detected in 14 cases (13.2%) and occurred in FAB types M1 (4 out of 14 cases), M3 (1 out of 10 cases), M4 (5 out of 37 cases) and M5 (4 out of 11 cases). Sequence analysis of four cases with abnormal PCR electrophoretic patterns revealed in frame duplications in the region of exon 11 of between 27 and 111 base pairs. Three are predicted to result in the tandem duplication of adjacent amino acid residues and one to result in a tandem duplication plus insertion of a novel amino acid motif. Statistical analysis showed the FLT3 mutations to be a strong prognostic factor, with patients lacking the mutation surviving significantly longer from diagnosis (mean 29.1 months) than those with an ITD (mean 12.8 months; P = 0.0002). Thirteen of the 14 patients with FLT3 mutations died within 18 months of diagnosis. FLT3 mutations were of prognostic significance in good risk disease (P = 0.04), as well as in patients with standard risk disease (P = 0.0096). This study demonstrates that the FLT3 ITD mutation occurs in a significant percentage of adult AML cases and is an important adverse prognostic factor that appears independent of conventional karyotypic findings.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091200     DOI: 10.1046/j.1365-2141.2000.02317.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  55 in total

1.  Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Authors:  Stephen A Strickland; Aaron C Shaver; Michael Byrne; Robert D Daber; P Brent Ferrell; David R Head; Sanjay R Mohan; Claudio A Mosse; Tamara K Moyo; Thomas P Stricker; Cindy Vnencak-Jones; Michael R Savona; Adam C Seegmiller
Journal:  Leuk Res       Date:  2018-01-02       Impact factor: 3.156

Review 2.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.

Authors:  Massimo Breccia; Giuseppina Loglisci; Maria Giovanna Loglisci; Roberto Ricci; Daniela Diverio; Roberto Latagliata; Robin Foà; Francesco Lo-Coco
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

4.  Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

Authors:  Catherine C Smith; Elisabeth A Lasater; Xiaotian Zhu; Kimberly C Lin; Whitney K Stewart; Lauren E Damon; Sara Salerno; Neil P Shah
Journal:  Blood       Date:  2013-02-21       Impact factor: 22.113

5.  Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib.

Authors:  Cheryl A C Peretz; Lisa H F McGary; Tanya Kumar; Hunter Jackson; Jose Jacob; Robert Durruthy-Durruthy; Mark J Levis; Alexander Perl; Benjamin J Huang; Catherine C Smith
Journal:  Blood Adv       Date:  2021-03-09

Review 6.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

7.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Authors:  Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

Review 8.  Is it important to decipher the heterogeneity of "normal karyotype AML"?

Authors:  Stephen D Nimer
Journal:  Best Pract Res Clin Haematol       Date:  2008-03       Impact factor: 3.020

9.  Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Authors:  Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-03       Impact factor: 3.333

10.  Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.

Authors:  Mamdooh Gari; Adel Abuzenadah; Adeel Chaudhary; Mohammed Al-Qahtani; Huda Banni; Waseem Ahmad; Fatin Al-Sayes; Sahira Lary; Ghazi Damanhouri
Journal:  Int J Mol Sci       Date:  2008-11-11       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.